» Articles » PMID: 34092785

Plasma Lipidome is Dysregulated in Alzheimer's Disease and is Associated with Disease Risk Genes

Overview
Date 2021 Jun 7
PMID 34092785
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Lipidomics research could provide insights of pathobiological mechanisms in Alzheimer's disease. This study explores a battery of plasma lipids that can differentiate Alzheimer's disease (AD) patients from healthy controls and determines whether lipid profiles correlate with genetic risk for AD. AD plasma samples were collected from the Sydney Memory and Ageing Study (MAS) Sydney, Australia (aged range 75-97 years; 51.2% male). Untargeted lipidomics analysis was performed by liquid chromatography coupled-mass spectrometry (LC-MS/MS). We found that several lipid species from nine lipid classes, particularly sphingomyelins (SMs), cholesterol esters (ChEs), phosphatidylcholines (PCs), phosphatidylethanolamines (PIs), phosphatidylinositols (PIs), and triglycerides (TGs) are dysregulated in AD patients and may help discriminate them from healthy controls. However, when the lipid species were grouped together into lipid subgroups, only the DG group was significantly higher in AD. ChEs, SMs, and TGs resulted in good classification accuracy using the Glmnet algorithm (elastic net penalization for the generalized linear model [glm]) with more than 80% AUC. In general, group lipids and the lipid subclasses LPC and PE had less classification accuracy compared to the other subclasses. We also found significant increases in SMs, PIs, and the LPE/PE ratio in human U251 astroglioma cell lines exposed to pathophysiological concentrations of oligomeric Aβ. This suggests that oligomeric Aβ plays a contributory, if not causal role, in mediating changes in lipid profiles in AD that can be detected in the periphery. In addition, we evaluated the association of plasma lipid profiles with AD-related single nucleotide polymorphisms (SNPs) and polygenic risk scores (PRS) of AD. We found that FERMT2 and MS4A6A showed a significantly differential association with lipids in all lipid classes across disease and control groups. ABCA7 had a differential association with more than half of the DG lipids (52.63%) and PI lipids (57.14%), respectively. Additionally, 43.4% of lipids in the SM class were differentially associated with CLU. More than 30% of lipids in ChE, PE, and TG classes had differential associations with separate genes (ChE-PICALM, SLC24A4, and SORL1; PE-CLU and CR1; TG-BINI) between AD and control group. These data may provide renewed insights into the pathobiology of AD and the feasibility of identifying individuals with greater AD risk.

Citing Articles

Regulation of lipid dysmetabolism and neuroinflammation linked with Alzheimer's disease through modulation of Dgat2.

Yadav A, Ouyang X, Barkley M, Watson J, Madamanchi K, Kramer J bioRxiv. 2025; .

PMID: 40027815 PMC: 11870505. DOI: 10.1101/2025.02.18.638929.


Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.

Hernandez P, Rackles E, Alboniga O, Martinez-Lage P, Camacho E, Onaindia A J Extracell Vesicles. 2025; 14(2):e70043.

PMID: 39901643 PMC: 11791017. DOI: 10.1002/jev2.70043.


Lipids: Emerging Players of Microglial Biology.

Prakash P, Randolph C, Walker K, Chopra G Glia. 2024; 73(3):657-677.

PMID: 39688320 PMC: 11784843. DOI: 10.1002/glia.24654.


Four-Dimensional Lipidomic Analysis Using Comprehensive Online UHPLC × UHPSFC/Tandem Mass Spectrometry.

Lasko Z, Hajek T, Jirasko R, Peterka O, Simek P, Schoenmakers P Anal Chem. 2024; 96(49):19439-19446.

PMID: 39602178 PMC: 11635755. DOI: 10.1021/acs.analchem.4c03946.


Exploring the Dynamic Changes of Brain Lipids, Lipid Rafts, and Lipid Droplets in Aging and Alzheimer's Disease.

Cerasuolo M, Di Meo I, Auriemma M, Paolisso G, Papa M, Rizzo M Biomolecules. 2024; 14(11).

PMID: 39595539 PMC: 11591903. DOI: 10.3390/biom14111362.


References
1.
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J, Carrasquillo M . Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011; 43(5):429-35. PMC: 3084173. DOI: 10.1038/ng.803. View

2.
Apostolova L, Risacher S, Duran T, Stage E, Goukasian N, West J . Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurol. 2018; 75(3):328-341. PMC: 5885860. DOI: 10.1001/jamaneurol.2017.4198. View

3.
Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S . Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 2016; 12(7):815-22. PMC: 4947451. DOI: 10.1016/j.jalz.2015.12.008. View

4.
Jacobsen L, Madsen P, Jacobsen C, Nielsen M, GLIEMANN J, Petersen C . Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001; 276(25):22788-96. DOI: 10.1074/jbc.M100857200. View

5.
Smith M, Rottkamp C, Nunomura A, Raina A, Perry G . Oxidative stress in Alzheimer's disease. Biochim Biophys Acta. 2000; 1502(1):139-44. DOI: 10.1016/s0925-4439(00)00040-5. View